Domain Invest

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Monday, 13 August 2007

While You Were at the Beer Festival

Posted on 04:00 by Unknown
A friend of IN VIVO Blog reads his GBBF-approved magazine

Massive beer festivals and keeping up with the weekend's news don't necessarily mix, but damnit we'll do our best.
  • Glass half-full ... The Boston Globe is reporting this morning that FoldRx, a biotech specializing in molecular chaperones that can return misfolded proteins to their correct shapes, will receive a serious chunk of change from the Cystic Fibrosis Foundation. The $22 million grant will be paid out over five years, says the Globe (Our most recent feature on venture philanthropy can be found here.)
  • Glass half-empty ... Cost cutting: not just for Big Pharma. Amgen isn't saying what the cuts will look like, but the big biotech said in a regulatory filing on Friday that hits to its ESA franchise will result in a fresh look at its cost structure.
  • Through the Looking Glass ... we've ignored this blog-friendly story so far if only because we don't have much to add beyond "eeesh." But for a roundup of the Johnson & Johnson-sues-the-Red Cross kerfuffle, and the various guffaws and high-horsing around the web, see the never-subtle Pharma Marketing Blog.
  • What's in your glass? Finally, some tasting notes from the Great British Beer Festival for any ale aficionados out there ...

As you can see from the picture above we spent some time camped out in front of the Caledonian and Sharps booths, mostly because these breweries rarely disappoint. The XPA and Deuchars IPA were outstanding as usual, and the mysterious Rebus 20 was also quite good. Sharps' Atlantic IPA was delicious and we also liked their Cornish Coaster. No surprises there.

What did surprise us a bit were the higher-than-the-pub prices for some beers at the festival (3 quid per pint was not uncommon), and the fact that we 'discovered' only a few new ales that were top-notch. (That said, we couldn't try all 450. Maybe next year.)

Can't wait to try again: Jennings Cocker Hoop from Marston's and Caledonian's XPA.

Give it a miss: A Fist Full of Hops from Falstaff and Bullmastiff South's Welsh Gold.

If you were at the festival or just have a favorite ale to tell us about, lets hear it in the comments...

Email ThisBlogThis!Share to XShare to Facebook
Posted in mmm beer, While You Were ... | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Ventana Accepts $3.4 Billion
    Roche finally nabs its man. Or in this case, its diagnostics company. All it took was an extra $14.50 per share. From the companies' pre...
  • Merck: Embracing Externalization, From the Top Down
    Updated Below . One business magazine greeted the tenure of Dick Clark as Merck's new CEO in 2005 with the instruction to "say hel...
  • While You Were Coming Back
    It would be wrong for us not to mention the Red Sox in this space, the Boston nine having completed their three-game comback victory over th...
  • Unusual Suspects: If Pfizer Decides to Really Rattle the R&D Cages
    Yesterday, we listed a group of people -- we called them the usual suspects -- that we think Pfizer will try to woo if it ends up turning to...
  • Avandia and Rezulin: Parallels that Should Make GSK Nervous
    History doesn’t repeat itself but it does rhyme. That old Mark Twain saying must be making GlaxoSmithKline sweat as Avandia is starting to ...
  • Private Equity Goes Public
    One of the simplest metrics we have to measure interest in a company or industry is just how jammed the rooms are at the JP Morgan conferenc...
  • High Noon at Myogen
    Most VC meetings provide a feel-good story for the portfolio CEOs—usually a variation on the business resurrection theme. The Atlas Venture ...
  • While You Were Watching the Upsets
    This weekend we were in Cardiff for the Rugby World Cup quarterfinal between France and New Zealand, which saw France upsetting the favorite...
  • Deals of the Week: You Can't Always Get What You Want
    It's been a busy--and, for some, disheartening--week in biopharma land. Just three days after researchers disclosed that Vytorin , the h...
  • Sorry, I Still Don’t Get It
    Pfizer launched its first TV campaign for Exubera this past week in an attempt to breathe a little life into the stalled inhaled insulin br...

Categories

  • Abbott
  • activist shareholders
  • ADHD
  • advisory committees
  • alliances
  • Alnylam
  • Alzheimer's disease
  • Amgen
  • Andrew von Eschenbach
  • Andrew Witty
  • Astellas
  • AstraZeneca
  • Avandia
  • Avastin
  • Barack Obama
  • Barr
  • Bayer
  • Big Pharma
  • BIO
  • Biogen Idec
  • biologics
  • biosimilars
  • blogging
  • BMS
  • Boston Scientific
  • brand names
  • business development
  • business models
  • cancer vaccines
  • Carl Icahn
  • CBO
  • CDER
  • Celgene
  • Cephalon
  • China
  • clinical development
  • CMS
  • co-promotes
  • comparative effectiveness
  • conference
  • Congress
  • consumer genomics
  • corporate culture
  • corporate governance
  • corporate venture capital
  • CVS Caremark
  • Cytyc
  • David Kessler
  • deals of the week
  • debt financing
  • Diabetes
  • diagnostics
  • Dick Clark
  • drug approvals
  • drug delivery
  • drug discovery
  • drug eluting stents
  • Drug Pricing
  • drug safety
  • drug samples
  • DTC Advertising
  • e-health
  • Eisai
  • Elan
  • Eli Lilly
  • Emphasys
  • emphysema
  • Endo
  • epo
  • Euro-Biotech Forum
  • Exits
  • Exubera
  • FDA
  • FDA/CMS Summit
  • FDAAA
  • Film and TV
  • financing
  • FOBs
  • Forest Labs
  • Galvus
  • gene therapy
  • Genentech
  • General Electric
  • generics
  • Genzyme
  • Gleevec
  • Google
  • GSK
  • Guidant
  • haircuts
  • Happy Holidays
  • HCV
  • Headhunting
  • Health Care Reform
  • hedge funds
  • Henry Waxman
  • hGH
  • HHS
  • Hillary Clinton
  • Hologic
  • hostile takeovers
  • hypertension
  • ImClone
  • IMS Health
  • In vitro diagnostics
  • In3
  • India
  • insomnia
  • instrumentation
  • insulin
  • Inverness
  • IP
  • IPO
  • IPO pricing
  • Isis Pharmaceuticals
  • Israel
  • IT
  • JAMA
  • Januvia
  • Japan
  • John McCain
  • Johnson and Johnson
  • JP Morgan
  • LaMattina
  • lawsuits
  • layoffs
  • legislation
  • Life-Cycle Management
  • Lipitor
  • Lucentis
  • management succession
  • Mark McClellan
  • marketing
  • Martin Mackay
  • medical devices
  • Medicare
  • Medicare Part D
  • Medimmune
  • Medtech Insight
  • Medtronic
  • Merck
  • Merck-Serono
  • mergers and acquisitions
  • Michael McCaughan
  • Millennium
  • mmm beer
  • MRI
  • multiple sclerosis
  • music
  • nanotechnology
  • NEJM
  • new drug approvals
  • new funds
  • NICE
  • NicOx
  • NIH
  • Nobel Prize
  • Novartis
  • Novo Nordisk
  • Nycomed
  • off-label promotion
  • oncology
  • ophthalmology
  • Orthopedics
  • osteoporosis
  • OTC drugs
  • Out-Partnering
  • Oxycontin
  • pain
  • Part D
  • Patient Advocacy
  • PDUFA
  • personalized medicine
  • Pfizer
  • pharmacy benefits
  • PhRMA
  • politics
  • poll results
  • PR
  • prasugrel
  • Presidential Election
  • Press Release of the Week
  • Primary Care
  • private equity
  • Procter and Gamble
  • PSA
  • Purdue Pharma
  • rare diseases
  • reimbursement
  • research and development productivity
  • research and development strategies
  • reverse mergers
  • rimonabant
  • RiskMAP
  • RNAi
  • Roche
  • Roger Longman
  • royalties
  • sales forces
  • Sanofi-aventis
  • Schering-Plough
  • Science Matters
  • Sepracor
  • shameless self-promotion
  • share buybacks
  • Shire
  • Sirtris
  • Smith and Nephew
  • Solvay
  • SPACs
  • spec pharma
  • spin-outs
  • sports
  • Start-Up
  • statins
  • Steve Nissen
  • Stryker
  • Supreme Court
  • Takeda
  • Teva
  • Thanksgiving
  • The RPM Report
  • UCB
  • vaccines
  • Velcade
  • Ventana
  • venture capital
  • venture debt
  • Venture Round
  • Vertex
  • Vioxx
  • Vytorin
  • Wacky World of Generics
  • While You Were ...
  • Wyeth
  • Zetia
  • Zimmer
  • ZymoGenetics

Blog Archive

  • ►  2008 (76)
    • ►  February (25)
    • ►  January (51)
  • ▼  2007 (329)
    • ►  December (32)
    • ►  November (42)
    • ►  October (37)
    • ►  September (33)
    • ▼  August (29)
      • Generic EPO Should be a Big Deal. But Is It?
      • Is it Getting Breezy in Here?
      • Bayer-Schering Biz Dev: Reorganized and Ready to Deal
      • The One-Two Punch in Venture Capital
      • While You Were Redesigning Your Blog
      • No Wait! Make it a Venti!
      • Ready, set....
      • Take The Money and Run
      • Old Medicine in New Bottles
      • CardioNet's Not So Big Surprise
      • While You Were Watching the Weather Channel
      • Seeing Double: Ophthotech's $36mm Series A
      • Avandia and Rezulin Redux
      • They MIGHT Be Giants
      • Wyeth's Leaky Pipeline
      • Northwest Under the Hammer
      • The Most Important Deal of the Last 12 Months
      • While You Were at the Beer Festival
      • Are These Large-Molecule Twins Identical? The Bios...
      • The Return of Lord Kesslermort
      • Another Co-Promote Bites the Dust
      • FDA and Drug Safety: It Keeps Getting Worse
      • Insight + Preparation + Dumb Luck = Blockbuster
      • Medtronic/Kyphon: Averting a Shake-Up in Spine...F...
      • Drug Safety...or Food Safety...or Tobacco Safety.....
      • While You Were Making History*
      • Once in a Blue Moon: SGP's Stock Offering
      • Novartis: Having & Eating Its Cake
      • Is Partial Agonism the Key to PPAR Success?
    • ►  July (39)
    • ►  June (39)
    • ►  May (43)
    • ►  April (16)
    • ►  March (13)
    • ►  February (5)
    • ►  January (1)
  • ►  2006 (8)
    • ►  December (3)
    • ►  November (5)
Powered by Blogger.

About Me

Unknown
View my complete profile